Institutional investors purchased a net $24.1 million shares of VRX during the quarter ended March 2017 and now own 52.74% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Pharmaceuticals: Other industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
PAULSON & CO., INC. Bought 2.4 Million shares of Valeant Pharmaceuticals